Citizens reiterates Market Outperform rating on Pharvaris stock ahead of trial data

Citizens reiterated a Market Outperform rating and $52 price target on Pharvaris ahead of RAPIDe‑3 data, noting the $1.73bn market cap stock trades at $23.97 with analyst targets of $26.93–$59.73 and InvestingPro flagging a slight undervaluation; the focus is on deucrictibant’s clinical profile where a 1.1‑hour time to symptom relief in a Phase 2 open‑label extension could compare favorably with Ekterly’s 2‑hour onset in Phase 3. Investors are watching dosing convenience—deucrictibant is a single pill versus Ekterly’s initial two‑tablet 600 mg regimen (with 38% of patients requiring a second dose)—and Citizens says superior onset could lift PHVS above $30, comparable results could see shares in the low $20s, while a prophylactic opportunity cushions downside. Analyst interest has strengthened (H.C. Wainwright reaffirmed Buy, $60 PT; BofA upgraded to Neutral, $27 PT), the stock has rallied ~43.6% over six months, and the company’s strong liquidity (current ratio 12.86, more cash than debt) provides financial runway through pivotal data readouts.

Analysis

Citizens has reiterated a Market Outperform and $52 price target on Pharvaris ahead of the RAPIDe-3 readout; the company trades at $23.97 with a $1.73bn market cap and analyst targets spanning $26.93–$59.73, while InvestingPro flags the stock as slightly undervalued. The pivotal clinical metric investors are watching is deucrictibant’s time to onset: Pharvaris reported a 1.1-hour onset in a Phase 2 open‑label extension versus Ekterly’s 2‑hour onset in Phase 3, and Citizens emphasizes that a demonstrably faster onset would be positively received. Administration convenience is another competitive variable: deucrictibant is a single pill versus Ekterly’s initial two‑tablet 600 mg dose (38% of patients required a second dose in Ekterly’s Phase 3), and Citizens models outcomes that could lift PHVS above $30 with superior data or leave it in the low $20s with comparable results. The company’s balance sheet is a strength—current ratio 12.86 and more cash than debt—supporting the program through the binary RAPIDe‑3 catalyst, but the Phase 2 program did not evaluate the primary endpoint, so trial risk remains material despite positive analyst sentiment (H.C. Wainwright $60 PT; BofA Neutral $27).

Key Decisions for Investors

• Consider a size‑limited, event‑driven long position ahead of RAPIDe‑3 to capture upside if deucrictibant demonstrates a faster onset (Citizens cites potential to move above $30), but cap position size given the binary clinical readout risk
• Hedge event exposure through protective puts or call spreads or set predefined stop/sell levels because Citizens models a downside scenario into the low $20s if data are only comparable to Ekterly
• Monitor the RAPIDe‑3 onset and dosing details closely and watch for analyst revisions (H.C. Wainwright $60, Citizens $52, BofA $27); be prepared to add on clear negative-price dislocations given the company’s strong liquidity and prophylactic opportunity